My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 268

    1.

    Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.

    Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E.

    Diabetes Care. 2005 May;28(5):1132-8.PMID: 15855578 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

    Gribble FM, Manley SE, Levy JC.

    Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.

    Lindsay JR, McKillop AM, Mooney MH, O'Harte FP, Flatt PR, Bell PM.

    Diabetes Res Clin Pract. 2003 Sep;61(3):167-73.PMID: 12965106 [PubMed - indexed for MEDLINE]Related articles

    4.

    Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

    Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

    Diabetes Care. 2001 Jun;24(6):983-8.PMID: 11375357 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

    Hanefeld M, Bouter KP, Dickinson S, Guitard C.

    Diabetes Care. 2000 Feb;23(2):202-7.PMID: 10868832 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.

    Walter YH, Spratt DI, Garreffa S, McLeod JF.

    Eur J Clin Pharmacol. 2000 May;56(2):129-33.PMID: 10877006 [PubMed - indexed for MEDLINE]Related articles

    7.

    Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine an optimal indication for nateglinide.

    Mori Y, Ishii H, Hikita M, Tajima N.

    Adv Ther. 2003 Nov-Dec;20(6):352-9.PMID: 15058753 [PubMed - indexed for MEDLINE]Related articles

    8.

    Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

    Horton ES, Foley JE, Shen SG, Baron MA.

    Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

    9.

    A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.

    Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S.

    Diabet Med. 2004 Sep;21(9):983-6.PMID: 15317602 [PubMed - indexed for MEDLINE]Related articles

    10.

    Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.

    Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T.

    Clin Transplant. 2007 Mar-Apr;21(2):246-51.PMID: 17425753 [PubMed - indexed for MEDLINE]Related articles

    11.

    Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

    Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

    Diabetes Care. 2000 Mar;23(3):349-53.PMID: 10868864 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.

    Dashora UK, Sibal L, Ashwell SG, Home PD.

    Diabet Med. 2007 Apr;24(4):344-9. Epub 2007 Jan 12.PMID: 17298589 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.

    González-Ortiz M, Hernández-Salazar E, Martínez-Abundis E.

    J Diabetes Complications. 2005 Nov-Dec;19(6):356-60.PMID: 16260353 [PubMed - indexed for MEDLINE]Related articles

    14.

    Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.

    Kalbag JB, Walter YH, Nedelman JR, McLeod JF.

    Diabetes Care. 2001 Jan;24(1):73-7.PMID: 11194245 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.

    Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, Li Y, Huang L.

    Diabetes Obes Metab. 2007 Jul;9(4):558-65.PMID: 17587398 [PubMed - indexed for MEDLINE]Related articles

    16.

    Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.

    Saloranta C, Guitard C, Pecher E, De Pablos-Velasco P, Lahti K, Brunel P, Groop L.

    Diabetes Care. 2002 Dec;25(12):2141-6.PMID: 12453951 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.

    Kahn SE, Montgomery B, Howell W, Ligueros-Saylan M, Hsu CH, Devineni D, McLeod JF, Horowitz A, Foley JE.

    J Clin Endocrinol Metab. 2001 Dec;86(12):5824-9.PMID: 11739446 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.

    Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.

    Diabetes Care. 2006 Feb;29(2):189-94.PMID: 16443858 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.

    Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M.

    Diabetes Res Clin Pract. 2006 Mar;71(3):251-5. Epub 2005 Oct 7.PMID: 16214255 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.

    Whitelaw DC, Clark PM, Smith JM, Nattrass M.

    Diabet Med. 2000 Mar;17(3):225-9.PMID: 10784228 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity